Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. - Wikidata - wikimedia - TriplyDB

Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

http://www.wikidata.org/entity/Q37336611

about

Synthesis and evaluation of fluorine-substituted phenyl acetate derivatives as ultra-short recovery sedative/hypnotic agents AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis.Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate.Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology Molecular approaches to improving general anesthetics Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs.Anesthetic drug development: Novel drugs and new approaches.The neurosteroid 5β-pregnan-3α-ol-20-one enhances actions of etomidate as a positive allosteric modulator of α1β2γ2L GABAA receptors Clinical and molecular pharmacology of etomidate.Etomidate and Ketamine: Residual Motor and Adrenal Dysfunction that Persist beyond Recovery from Loss of Righting Reflex in Rats Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia.In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate.Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite Active emergence from propofol general anesthesia is induced by methylphenidate.Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized etomidate analog in rats.Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs.Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action.Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function Distinct Hypnotic Recoveries After Infusions of Methoxycarbonyl Etomidate and Cyclopropyl Methoxycarbonyl Metomidate: The Role of the Metabolite γ-Aminobutyric Acid Type A Receptor Modulation by Etomidate Analogs.The discovery of new anesthetics by targeting GABA(A) receptors.The role of etomidate as an anaesthetic induction agent for critically ill patients.Mapping General Anesthetic Sites in Heteromeric γ-Aminobutyric Acid Type A Receptors Reveals a Potential For Targeting Receptor Subtypes.Pharmacologic Considerations for Pediatric Sedation and Anesthesia Outside the Operating Room: A Review for Anesthesia and Non-Anesthesia Providers.The future of anaesthetic pharmacology.Minimum infusion rate and adrenocortical function after continuous infusion of the novel etomidate analog ET-26-HCl in rats.Getting oil and water to mix Sedative-hypnotic Binding to 11β-hydroxylase.Dimethoxy-etomidate: A Non-hypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.The Role of GABA Receptor Agonists in Anesthesia and Sedation.The etomidate analog ET-26 HCl retains superior myocardial performance: Comparisons with etomidate in vivo and in vitro.Etomidate derivatives: Novel pharmaceutical agents in anesthesia.[Etomidate for intravenous induction of anaesthesia].Recent advances in intravenous anesthesia and anesthetics.Pretreatment with lidocaine reduces both incidence and severity of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials

P2860

Q28538503-5C4C42EA-1731-477C-8951-394AAF860534 Q30580658-E16A11B1-AC33-4F82-BDD3-F363AAF466DE Q33697203-98B97F76-31C3-4148-A1EF-5019B2BB554F Q33753539-AD0B1EC6-31A0-4D92-9C6E-EDC3BD36DFC2 Q34001757-92600100-95AB-4588-8B76-6224853A46ED Q34346105-E1BBA0CD-A775-4869-A41A-CC91B5231353 Q34543679-7464736F-58D5-44FC-99D9-DBBD6B037412 Q34710067-728CE81E-85A3-47C4-94C0-24CE5BC014C5 Q34953451-0C4F49E1-6853-40D3-BDFB-8554310B26D4 Q35024852-622CC6E4-592D-4F69-A715-C97DD4DA733F Q35536303-F643E12D-C749-41F4-985A-669A3682DC7D Q35624083-21F11976-A205-470C-9092-C7F2CAA01651 Q35656186-91F28A76-1F77-43B0-9B98-A8D05EDA0428 Q35795130-F93CB762-9578-4280-AD8B-8D60EDA6F4A1 Q35920648-7AAC49B5-6535-4B60-AD52-1499B1F29389 Q35958072-8C1A942D-F5DC-48C9-9205-724BD9FDE937 Q36431847-C2EC4584-002F-45D5-B399-9C4EC520679E Q36431861-EBDCDC35-9ED6-4D7F-BC7E-D75370E0E2BC Q36501060-CA6154B4-A310-44D7-B8E9-19FB2E224389 Q36709331-15E6C784-DCCB-41EC-89DD-5FAE3CF65E0B Q36716721-CEA46353-515B-490B-AA1E-1A60FB8DDB1D Q38014564-7484EC69-ACA0-44B3-ABBB-1A7EC9AB8C15 Q38831520-BEDBB0DF-587A-4D6C-9D7B-0EEDFF38E431 Q38831924-956C2698-640E-40ED-B3CA-34245F21C9F5 Q39361432-2F4477D0-5FB1-415F-B47D-932A0B9CBCF1 Q39855676-6CC8DDC8-A953-44FF-B876-BED4BB4B9FCD Q41588695-FE4566C0-7DF5-41BF-AEA9-E41777A152CC Q42536861-A6414053-E5CC-4605-930D-C764EDEE5041 Q42707315-B5FF5CEE-D5ED-4216-B60F-83C72A371AB3 Q47224599-289FC97C-986F-45CA-891A-463200A3F3C5 Q47241038-F8E6B328-3D86-4244-AF7F-A76ADF7227E6 Q48258958-E1E9A8EA-8EDA-4596-86F9-CD643F0A0691 Q49622479-1EC69404-684C-4C22-B1F5-05BFD777539F Q49939100-7370FA3A-CB4A-4945-8887-7A0D471C3EED Q55129735-81E8E1AA-DC8A-44AF-8A67-2590C4AEF2AF Q57483623-E8AA3F0C-EDCE-4ACB-A0C1-0D62E3615B1B

P2860

Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

http://www.wikidata.org/entity/Q37336611

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@en

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@nl

type

label

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@en

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@nl

prefLabel

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@en

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@nl

P1433

Q37336611-E9214B2F-0318-4772-8AD2-EBF34DB3B950

P1476

Q37336611-C33E14A2-722F-43FC-BAD1-A985D4018931

P2093

Q37336611-52CD8F29-6340-4A2F-B497-2C0BDE2E5E41

Q37336611-5F66AF5E-7935-4E7D-A41B-572711D7A418

Q37336611-B977D40F-E1A6-49FB-8CEF-FD3CB43A9B40

Q37336611-CCAFCE2B-ECAD-4627-A99E-2D2DB68B2107

Q37336611-EEE006B1-881F-4D1C-BD33-43CFC7A39F00

Q37336611-F2B8E119-59FB-45CF-B452-9870E7FD04AF

Q37336611-FDF6F9CA-90E1-42E4-976B-D26E29DC8C64

P2860

Q37336611-0ECB3D05-7BEA-4ED4-84D8-CCCCA6BE5EC5

Q37336611-107C0C2F-4D7A-4663-9BD6-A961FE471CD5

Q37336611-2D2E63C5-FF63-4470-9211-C3096004FF1F

Q37336611-3E5FEAE8-32C8-4D7B-9127-FA52CF62201E

Q37336611-40123C94-3317-4BB3-A667-56F7225929F2

Q37336611-41BDBA7E-0AAB-4942-80ED-547B0ABC870E

Q37336611-4A7C0F0C-44DF-47B0-9D12-301F57A0C01D

Q37336611-4A8A5ED0-A421-4077-873E-0780CCD9F759

Q37336611-4B525969-5682-4CC3-8884-E1E2D94514C6

Q37336611-4B940E13-2E24-48D8-82BC-5AD88EC7AE8D

P304

Q37336611-27508EE7-E851-435A-AC8C-D7B4AED4844D

P31

Q37336611-B637CD08-C409-4E30-BEFC-A9ED4A6D2BA5

P356

Q37336611-388F7984-1AA3-4ED9-BA86-F59BC2AEB06E

P407

Q37336611-3F4D1399-6507-48EE-9177-14F5C344DBD0

P433

Q37336611-6EB0D7B7-CD94-4CE2-9C06-ED94EC77C9E3

P478

Q37336611-ED95A593-A1C1-48F1-ABA7-1FD1372C2F58

P577

Q37336611-EB1E7281-CE7F-4192-8999-423AFC47D223

P698

Q37336611-E42912C4-7D7D-40A1-91DD-2942706A075A

P932

Q37336611-8C87624E-68AB-437F-B060-72563E39500C

P356

ALN.0B013E3181AE63D1

P1433

P1476

Methoxycarbonyl-etomidate: a n ...... ed adrenocortical suppression.

@en

P2093

Douglas E Raines

http://www.w3.org/2001/XMLSchema#string

Elizabeth W Kelly

http://www.w3.org/2001/XMLSchema#string

Hieu H Nguyen

http://www.w3.org/2001/XMLSchema#string

Joseph F Cotten

http://www.w3.org/2001/XMLSchema#string

Keith W Miller

http://www.w3.org/2001/XMLSchema#string

S Shaukat Husain

http://www.w3.org/2001/XMLSchema#string

Stuart A Forman

http://www.w3.org/2001/XMLSchema#string

P2860

One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis

Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies

Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality

Duration of adrenal inhibition following a single dose of etomidate in critically ill patients

Hydrocortisone therapy for patients with septic shock

Inhibition of adrenal steroidogenesis by the anesthetic etomidate

Sympathetic responses to induction of anesthesia in humans with propofol or etomidate

Increased Risk of Adrenal Insufficiency Following Etomidate Exposure in Critically Injured Patients

INFLUENCE OF SEDATION ON MORTALITY IN CRITICALLY ILL MULTIPLE TRAUMA PATIENTS

Soft drug design: general principles and recent applications.

P304

240-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/ALN.0B013E3181AE63D1

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19625798

http://www.w3.org/2001/XMLSchema#string

P932

2739411

http://www.w3.org/2001/XMLSchema#string